ARC-520 - Some Information Found

[twinboys1girl4me]

You can listen to the webcast from the presentation ARC gave yesterday by the first link given.  They responded on ARC-520 as well as some others they are testing.  Also, if you click on the 2nd link below it gives a presentation that I believe was presented at the IBC's 17th Annual TIDES Conference in San Diego a few days ago.

Webcast link:  http://ir.arrowheadresearch.com/events.cfm  

Slideshow link:  http://files.shareholder.com/downloads/AMDA-2OTJP1/155364282x0x826969/60e17fbd-fb6f-419b-af88-199a53960b95/2015_TIDES_Lewis_HBV_F12_FINAL.pdf

I would LOVE some enlightenment from other more experienced, as I couldn't tell if anything surprisingly new came out from all of this or not, from both the webcast that I listened to or the slideshow.  Thanks and I hope this helps!

[studyforhope]

It shows that the best result they were able to get thus far was a temporary hbsag reduction by a factor of two. At 2mg/kg.

In comparison replicor achieved a reduction by a factor of one hundred thousand or a million for many month. This by itself was still not able to establish a permanent internal control over the remaining HBV remnants, so the majority of patients rebounded after stop of therapy.
With immuncombo therapy the long term stability of the SVR seems to be much better, but a long follow up observation is needed to confirm that stabilization.Furthermore all were e ag pos, a population that is much easier to stably seroconvert, since the e antigen prevented the need for immunoadaptive escape mutations in the core and e antigen region, that is most critical for TCell control.

[sorte]

thanks for the links ! comments please :)
I like the slides on pages 6-7, it explains a lot (in a very simplified way, I suppose) how virus works.